Publication number: 20180348195
Abstract: An objective biomarker is capable of evaluating the severity of depression and is clinically useful. The biomarker is used for evaluating the severity of depression, and includes at least one compound selected from the group made of 4-aminobutyric acid (? (gamma)-aminobutyric acid: GABA), arginine, argininosuccinate, isoleucine, indole carboxaldehyde, potassium indoleacetate, carnitine, acetylcarnitine, ornithine, xanthurenate, kynurenate, kynurenine, citrate, creatine, creatinine, glutamine, dimethylglycine, serotonin, taurine, trimethyloxamine (TMAO), tryptophan, norvaline, 3-hydroxybutyrate, phenylalanine, proline, betaine, and lysine.
Type:
Application
Filed:
October 31, 2016
Publication date:
December 6, 2018
Applicants:
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
Inventors:
Takahiro KATO, Daiki SETOYAMA, Dongchon KANG, Shigenobu KANBA, Ryota HASHIMOTO, Hiroshi KUNUGI, Kotaro HATTORI